U.S. Markets closed

Today's Research Reports on Centric Health, Hemostemix, CardioComm Solutions and Nuvo Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / August 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Centric Health Corporation
https://rdinvesting.com/news/?ticker=CHH.TO

Hemostemix Inc.
https://rdinvesting.com/news/?ticker=HEM.V

CardioComm Solutions, Inc.
https://rdinvesting.com/news/?ticker=EKG.V

Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO

Centric Health's stock had no change Tuesday, to close the day at $0.22. The stock recorded a trading volume of 70,505 shares, which was below its three months average volume of 145,993 shares. In the last year, Centric Health's shares have traded in a range of 0.21 - 0.81. The stock is currently trading 72.84% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.28 is below its 200-day moving average of $0.37. Shares of Centric Health have fallen approximately 57.69 percent year-to-date.

Access RDI's Centric Health Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CHH.TO

On Tuesday, shares of Hemostemix recorded a trading volume of 165,000 shares, which was below the three months average volume of 224,723 shares. The stock ended the day flat at 0.08. The share price has gained 60.00% from its 52-week low with a 52-week trading range of 0.05 - 0.16. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.07 is at its 200-day moving average of $0.07. Shares of Hemostemix have gained approximately 14.29 percent year-to-date.

Access RDI's Hemostemix Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HEM.V

CardioComm Solutions' stock had no change Tuesday, to close the day at $0.05. The stock recorded a trading volume of 4,000 shares, which was below its three months average volume of 144,411 shares. In the last year, CardioComm Solutions' shares have traded in a range of 0.05 - 0.08. The stock is currently trading 37.50% below its 52 week high. The company's shares are currently trading at their 200-day moving average. The stock's 50-day moving average of $0.05 is at its 200-day moving average of $0.05.

Access RDI's CardioComm Solutions, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EKG.V

On Tuesday, shares of Nuvo Pharmaceuticals recorded a trading volume of 400 shares, which was below the three months average volume of 12,579 shares. The stock ended the day 3.44% lower at 2.81. The stock is currently trading 39.57% below its 52-week high with a 52-week trading range of 2.60 - 4.65. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.89 is below its 200-day moving average of $3.09. Shares of the company are trading at a Price to Earnings ratio of 70.25. Shares of Nuvo Pharmaceuticals have fallen approximately 24.05 percent year-to-date.

Access RDI's Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO

Our Actionable Research on Centric Health Corporation (TSX: CHH.TO) and Hemostemix Inc. (TSX-V: HEM.V) and CardioComm Solutions, Inc. (TSX-V: EKG.V) and Nuvo Pharmaceuticals Inc. (TSX: NRI.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com